Search research articles
Contact Us
Filters
Showing results (1-10 of 534) with videos related to
Page
of 54
Sort By:
Clinical Immunology (Orlando, Fla.)
|
October 15, 2011
Is IL-4 a potential therapeutic target in systemic sclerosis-associated pulmonary fibrosis?
Petros P Sfikakis
Current Directions in Autoimmunity
|
February 23, 2010
The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions
Petros P Sfikakis
RMD Open
|
August 16, 2019
Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift
Katerina Chatzidionysiou, Petros P Sfikakis
The Journal of Rheumatology
|
May 5, 2004
Ophthalmologic monitoring for antimalarial toxicity
Petros P Sfikakis, Myron Mavrikakis
Current Opinion in Rheumatology
|
June 24, 2003
Tumor necrosis factor biology in experimental and clinical arthritis
Petros P Sfikakis, George Kollias
Arthritis and Rheumatism
|
April 29, 2008
Tumor necrosis factor inhibitors and uveitis: comment on the article by Lim et al
Petros P Sfikakis, Nikos Markomichelakis
Clinical and Experimental Rheumatology
|
October 1, 2014
Anti-cytokine biologic treatment beyond anti-TNF in Behçet's disease
Aikaterini Arida, Petros P Sfikakis
Hormones (Athens, Greece)
|
November 14, 2022
Cortisol and DHEAS in COVID-19
Maria P Yavropoulou, Petros P Sfikakis
Clinical Immunology (Orlando, Fla.)
|
October 19, 2011
Towards the next generation of anti-TNF drugs
Petros P Sfikakis, George C Tsokos
Mediterranean Journal of Rheumatology
|
March 19, 2020
Systemic lupus erythematosus with antiphospholipid syndrome: Cardiovascular magnetic resonance for evaluation of cardiac hypertrophy
Sophie I Mavrogeni, Petros P Sfikakis
Page
of 54
Search research articles
Search
Showing results (1-10 of 534) with videos related to
Sort By:
Page
of 54
Clinical Immunology (Orlando, Fla.)
|
October 15, 2011
Is IL-4 a potential therapeutic target in systemic sclerosis-associated pulmonary fibrosis?
Petros P Sfikakis
Current Directions in Autoimmunity
|
February 23, 2010
The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions
Petros P Sfikakis
RMD Open
|
August 16, 2019
Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift
Katerina Chatzidionysiou, Petros P Sfikakis
The Journal of Rheumatology
|
May 5, 2004
Ophthalmologic monitoring for antimalarial toxicity
Petros P Sfikakis, Myron Mavrikakis
Current Opinion in Rheumatology
|
June 24, 2003
Tumor necrosis factor biology in experimental and clinical arthritis
Petros P Sfikakis, George Kollias
Arthritis and Rheumatism
|
April 29, 2008
Tumor necrosis factor inhibitors and uveitis: comment on the article by Lim et al
Petros P Sfikakis, Nikos Markomichelakis
Clinical and Experimental Rheumatology
|
October 1, 2014
Anti-cytokine biologic treatment beyond anti-TNF in Behçet's disease
Aikaterini Arida, Petros P Sfikakis
Hormones (Athens, Greece)
|
November 14, 2022
Cortisol and DHEAS in COVID-19
Maria P Yavropoulou, Petros P Sfikakis
Clinical Immunology (Orlando, Fla.)
|
October 19, 2011
Towards the next generation of anti-TNF drugs
Petros P Sfikakis, George C Tsokos
Mediterranean Journal of Rheumatology
|
March 19, 2020
Systemic lupus erythematosus with antiphospholipid syndrome: Cardiovascular magnetic resonance for evaluation of cardiac hypertrophy
Sophie I Mavrogeni, Petros P Sfikakis
Page
of 54